statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cantor Fitzgerald initiated coverage on shares of Tango Therapeutics (NASDAQ:TNGX - Free Report) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. The firm...

Tango Therapeutics (NASDAQ:TNGX) Now Covered by Cantor Fitzgerald

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tango Therapeutics initiated with bullish view at Cantor Fitzgerald

This is a signal that TNGX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Tango Therapeutics (TNGX, $7.65) RSI Indicator left the oversold zone on April 01, 2024

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics (TNGX, $7.95) RSI Indicator left the oversold zone on March 28, 2024

In trading on Friday, shares of Tango Therapeutics Inc (TNGX) crossed below their 200 day moving average of 8.04, changing hands as low as 7.75 per share. Tango Therapeutics Inc shares are...

Tango Therapeutics Breaks Below 200-Day Moving Average - Notable for TNGX

Tango Therapeutics, Inc. (NASDAQ:TNGX  Free Report)  Analysts at Leerink Partnrs reduced their Q1 2024 earnings estimates for Tango Therapeutics in a research note issued to investors...

Tango Therapeutics, Inc. (NASDAQ:TNGX) to Post Q1 2024 Earnings of ($0.31) Per Share, Leerink Partnrs Forecasts

Tango Therapeutics price target raised by $1 at H.C. Wainwright, here's why

Advancements in Oncology Pipeline and Strong Cash Position HighlightedRelated Stocks: TNGX...

Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results

Tango Therapeutics reports Q4 EPS (32c), consensus (28c)

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Volume	447,982.00
52-Wk High	$13.03
52-Wk Low	$2.47

TNGX Tango Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals